Roche
FDA approves first diagnostic tool to target triple-negative breast cancer patients
March 11, 2019Sales and Marketing Cancer, Roche, Ventana, breast cancer, pharma
Roche’s Ventana PD-L1 Assay has become the first FDA-approved companion diagnostic for the identification of patients with triple-negative breast cancer …
Roche’s Tecentriq combo scoops up European approval in first-line metastatic lung cancer
March 8, 2019Medical Communications, Sales and Marketing Cancer, Europe, European Commission, NSCLC, Roche, lung cancer, pharma
Roche has announced the approval of the European Commission for its PD-L1 inhibitor Tecentriq (atezolizumab) when used in combination with …
Top Ten most popular articles on Pharmafile.com this week!
March 1, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, GP, Michael Cohen, Novartis, Roche, Sanofi, Senate, UK, crispr, top 10
As the CRISPR twins’ story unfolds, scientists revealed that the Chinese babies were likely altered in a way that improves …
Roche set to acquire Spark Therapeutics in $4.8 billion deal
February 25, 2019Sales and Marketing Roche, Spark Therapeutics, acquisition, gene therapy, pharma
Roche is set to fully acquire gene therapy Spark Therapeutics after entering into a definitive merger agreement, after the Boards …
Roche’s Perjeta secures NICE approval in adjuvant HER2+ metastatic breast cancer
February 15, 2019Medical Communications, Sales and Marketing NICE, Perjeta, Roche, pharma
NICE has announced its decision to authorise the use of Roche’s Perjeta (pertuzumab) on the NHS for the treatment of …
Genentech to develop ‘highly active cytokine’ with Xancor in deal worth $300m
February 6, 2019Research and Development Cancer, Genetech, IL-15 cytokine, Roche, Xancor, oncology
Roche’s Genentech unit has agreed to pay $120 million upfront as part of a research and licensing deal with California-based …
Roche pulls plug on Alzheimer’s drug after Phase 3 failure
January 30, 2019Research and Development AC Immune, Alzheimer's, Roche, crenezumab, pharma
Roche has announced that it is to terminate two Phase 3 studies investigating the efficacy of its anti-beta-amyloid molecule crenezumab …
Alexander Hardy returns to Genentech as new CEO
January 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Genentech, Roche, appointment, pharma
Genetech, the biotech subsidiary of Swiss firm Roche, has named its new CEO, revealing that Alexander Hardy will be returning …
Top Ten most popular articles on Pharmafile.com this week!
January 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Netherlands, Novo Nordisk, Roche, astra zeneca, prcing, sequiris, top 10, uk politics
Job switches were the theme of this week as AstraZeneca lost three, high levels executives to biotechs amid a restructuring …
Roche’s Genentech inks potential $2bn personalised cancer drug development deal
January 7, 2019Sales and Marketing Adaptive Biotechnologies, Cancer, Genentech, Roche, oncology, pharma
Roche’s Genentech is set to enter into a deal with Adaptive Biotechnologies to bolster its pursuits in the treatment of …
Gilead names Roche veteran Daniel O’Day as new CEO
December 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Gilead, Roche, appointment
Almost half a year since it was revealed that Gilead’s Dr John Milligan would be stepping down from his role …
Roche’s first-line Tecentriq combo scores accelerated FDA review
December 5, 2018Research and Development ASH 2018, Cancer, Roche, lung cancer, pharma, tecentriq
Roche’s immunotherapy Tecentriq has secured Priority Review from the FDA, the company has announced, in combination with carboplatin and etoposide …
Hemlibra shows “clinically meaningful” bleed control in paediatric haemophilia A patients
December 4, 2018Manufacturing and Production, Research and Development ASH 2018, Hemlibra, Roche, haemophilia, pharma
In another reveal at the American Society of Hematology (ASH) Annual Meeting 2018, Roche unveiled new Phase 3 findings for …
Roche chooses Veeva Vault PromoMats for digital asset management and content
December 4, 2018Manufacturing and Production, Medical Communications Roche, pharma, veeva
Today, at the 2018 Veeva Commercial & Medical Summit Europe, Roche (SWX:ROG) announced that it would be adopting Veeva Systems …
Top Ten most popular articles on Pharmafile.com this week
November 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, Immuno Biotech, NHS, Roche, autism, biosimilars, pharma, top ten
We’ve come to the end of November, and with only one month of the year left to go, the industry …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
